An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations

Non-small Cell Lung Cancer Clinical Trial

Official title:

An Open-label Study of the Oral Administration of ASP8273 in Patients With Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02192697
• Other study ID #: 8273-CL-0101
• Status: Terminated
• Phase: Phase 1/Phase 2
• Start date: January 23, 2014
• Est. completion date: June 14, 2017

Study information

• Verified date: October 2019
• Source: Astellas Pharma Inc
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Purpose of the study is to determine the following in patients with non-small cell lung cancer (NSCLC) harboring EGFR activating mutations.

• the safety and tolerability of ASP8273.

• the pharmacokinetics (PK) of ASP8273.

• the antitumor activity of ASP8273.

Description:

This study consists of Phase I and Phase II.

The objectives of Phase I are to determine the following in patients with non-small cell lung cancer (NSCLC) harboring EGFR activating mutations.

• safety and tolerability of ASP8273.

• the maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of ASP8273 based on the dose limiting toxicity (DLT) profile.

• pharmacokinetics (PK) of ASP8273.

• antitumor activity of ASP8273.

The objectives of Phase II are to determine the following at the RP2D of ASP8273 in patients with NSCLC harboring EGFR mutation.

• efficacy of ASP8273

• safety of ASP8273

• PK of ASP8273

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 124
• Est. completion date: June 14, 2017
• Est. primary completion date: January 15, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

• Histologically or cytologically confirmed diagnosis of NSCLC.

• Patients confirmed to have the del ex19, L858R, G719X, or L861Q mutation among the EGFR activating mutations (patients at the study site who are documented to have any of the above-stated EGFR activating mutations can be enrolled in the study).

• Life expectancy = 12 weeks based on the investigator's/subinvestigator's judgment.

• [Phase I]

• Patients who have previously been treated with EGFR tyrosine-kinase inhibitors (EGFR-TKIs)*

• Those who are not expected to show a therapeutic response to existing treatments in the investigator's/subinvestigator's opinion.

• [Phase II]

• Patients who have been confirmed to have progressive disease (PD) after previous treatment with EGFR-TKIs*; for those who have received 2 or more regimens of previous treatment, the last regimen before enrollment should have included EGFR-TKIs.

• *Erlotinib, gefitinib, and EGFR-TKIs under clinical investigation (e.g., neratinib, afatinib, dacomitinib)

• Expression of the EGFR-T790M mutation as confirmed by a tumor biopsy of the primary or metastatic lesions after confirmation of PD following previous treatment with EGFR-TKIs and before enrollment, or by a tumor tissue sample that had been collected and archived after confirmation of PD following previous treatment with EGFR-TKIs.

• At least 1 measurable lesion based on Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

Exclusion Criteria:

• Persistent clinical evidence of previous antitumor treatment related toxicity = Grade 2 using the Japan Clinical Oncology Group (JCOG) Japanese translation of the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (NCI CTCAE v4.0 - JCOG) (except alopecia and skin toxicities considered irrelevant in study enrollment by the investigator/sub-investigator).

• History of or concurrent interstitial lung disease

• Received treatment with a reversible EGFR-TKI (erlotinib or gefitinib) within 8 days before the start of the study treatment.

• Received previous treatment (except reversible EGFR-TKIs) intended to have antitumor effects or treatment with another investigational drug or an investigational device within 14 days before the start of the study treatment.

• Previously received treatment with EGFR-TKIs (e.g., CO-1686, AZD9291) that can inhibit EGFR with the T790M mutation.

• It is planned that the subject will undergo a surgical procedure during the course of the study or the subject still has an unhealed wound after previous surgery

• Symptomatic central nervous system (CNS) lesions.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Drug:
• ASP8273
Oral administration

Locations

Country	Name	City	State
Japan	Site: 4	Fukuoka
Japan	Site: 9	Fukuoka
Japan	Site: 8	Miyagi
Japan	Site: 7	Okayama
Japan	Site: 3	Osaka
Japan	Site: 6	Osaka
Japan	Site: 2	Shizuoka
Japan	Site: 1	Tokyo
Japan	Site: 5	Tokyo
Korea, Republic of	Site: 10	Seoul
Korea, Republic of	Site: 11	Seoul
Korea, Republic of	Site: 12	Seoul
Taiwan	Site: 13	Taipei
Taiwan	Site: 14	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
Astellas Pharma Inc

Countries where clinical trial is conducted

Japan,  Korea, Republic of,  Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase I: Safety and tolerability of ASP8273 as assessed by Dose Limiting Toxicities (DLTs)	A DLT is defined as any pre-determined toxicity that is related to study drug per the investigator and which occurs during Cycle 0 and Cycle 1 using the Japan Clinical Oncology Group (JCOG) Japanese translation of the Common Terminology Criteria for Adverse Events version 4.0 (CTCAE ver 4.0 - JCOG)	Up to Day 23
Primary	Phase II: Overall response rate (CR+PR) at Week 24	The overall response rate, which is defined as the proportion of subjects whose best overall response is rated as complete response (CR) or partial response (PR) according to RECIST Version 1.1, will be calculated	Week 24
Secondary	Phase I: Safety and tolerability of ASP8273 as assessed by adverse events (AEs)	An AE is defined as any untoward medical occurrence in a subject administered a study drug or has undergone study procedures and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product	Up to 18 months
Secondary	Phase I: Safety and tolerability of ASP8273 as assessed by laboratory tests	Laboratory tests to be conducted are hematology, biochemistry, urinalysis, coagulation profile, lipid panel and lymphocyte subpopulation	Up to 18 months
Secondary	Phase I: Safety and tolerability of ASP8273 as assessed by vital signs	Vital signs to be measured includes blood pressure, pulse rate and temperature	Up to 18 months
Secondary	Phase I: Safety and tolerability of ASP8273 as assessed by 12-lead ECG	including the assessment of QT intervals	Up to 18 months
Secondary	Phase I: Plasma concentrations of unchanged ASP8273		Up to Day 1 of Cycle 3
Secondary	Phase I: Urine concentrations of unchanged ASP8273		Up to Day 1 of Cycle 3
Secondary	Phase I: Overall response rate (CR+PR)	The overall response rate is defined as the proportion of subjects whose best overall response is rated as complete response (CR) or partial response (PR) according to RECIST Version 1.1, will be calculated	Up to 18 months
Secondary	Phase I: Disease control rate (CR+PR+SD)	The disease control rate is defined as the proportion of subjects whose best overall response is rated as CR, PR, or stable disease (SD) according to RECIST Version 1.1, will be calculated.	Up to 18 months
Secondary	Phase II: Plasma concentrations of unchanged ASP8273		Up to Day 1 of Cycle 3
Secondary	Phase II: Urine concentrations of unchanged ASP8273		Up to Day 1 of Cycle 3
Secondary	Phase II: Safety and tolerability of ASP8273 as assessed by adverse events (AEs)	An AE is defined as any untoward medical occurrence in a subject administered a study drug or has undergone study procedures and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product	Up to 18 months
Secondary	Phase II: Safety and tolerability of ASP8273 as assessed by laboratory tests	Laboratory tests to be conducted are hematology, biochemistry, urinalysis, coagulation profile, lipid panel and lymphocyte subpopulation	Up to 18 months
Secondary	Phase II: Safety and tolerability of ASP8273 as assessed by vital signs	Vital signs to be measured includes blood pressure, pulse rate and temperature	Up to 18 months
Secondary	Phase II: Safety and tolerability of ASP8273 as assessed by 12-lead ECG	including the assessment of QT intervals	Up to 18 months
Secondary	Phase II: Disease control rate	The disease control rate is defined as the proportion of subjects whose best overall response is rated as CR, PR, or stable disease (SD) according to RECIST Version 1.1, will be calculated.	Up to 18 months
Secondary	Phase II: Progression-free survival (PFS)		Up to 18 months
Secondary	Phase II: Overall survival (OS)		Up to 18 months
Secondary	Phase II: Overall response rate (CR+PR)	The overall response rate, which is defined as the proportion of subjects whose best overall response is rated as complete response (CR) or partial response (PR) according to RECIST Version 1.1, will be calculated	Up to 18 months

External Links

•   Link to results on the Astellas Clinical Study Results website